2 completed, 1 not yet recruiting, 1 recruiting, 1 unknown. .
Follow Invivoscribe, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay IdentiClone Dx TRG Assay - T-Cell Lymphoproliferative Disorder | Not yet recruiting | Invivoscribe, Inc. | 250 | 2025-06-02 | 2025-03-14 | |
| The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research Hematologic Diseases | Recruiting | Invivoscribe, Inc. | 2000 | 2024-03-30 | 2025-05-04 | |
| Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx IGH Assay IdentiClone Dx IGH (IC IGH Dx) Assay - B-Cell Lymphoproliferative Disorder | Completed | Invivoscribe, Inc. | 250 | 2024-01-02 | 2024-12-04 | |
| The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines nasal pharyngeal (NP) swab samples, peripheral blood draw - SARS-CoV-2 | Unknown | Invivoscribe, Inc. | 500 | 2020-06-01 | 2020-05-18 | |
| Minimal Residual Disease in Peripheral T-cell Lymphoma Tumor biopsy, Peripheral blood draw, Lymphotrack TCR clonality assay - Peripheral T Cell Lymphoma | Completed | Washington University School of Medicine | 44 | 2017-07-31 | 2024-05-16 |
Hematologic Diseases (1) · Lymphoma, T-Cell, Peripheral (1)
United States (4) · Germany (2) · Japan (2)
Jordon Thornes (1) · Neha Mehta-Shah, M.D. (1)
K12CA167540 (1)